Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 12/20 | 0.56 |
| ▸ | ACHE | P22303 | 8/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12666733 | 0.83 | CHEK1 (0.69) | CHEK1ACHEMAPTPIM1 | |
| SCHEMBL12666705 | 0.81 | MAPT (0.64) | CHEK1ACHEMAPTPDPK1ALK | |
| SCHEMBL12666785 | 0.81 | CHEK1 (0.49) | CHEK1ACHEMAPTPIM1PDPK1 | |
| SCHEMBL12666780 | 0.81 | PIM1 (0.49) | CHEK1ACHEMAPTPIM1 | |
| SCHEMBL12666721 | 0.79 | CHEK1 (0.56) | CHEK1ACHEMAPTPIM1ALK | |
| SCHEMBL1897331 | 0.78 | CHEK1 (0.51) | CHEK1ACHEMAPTPIM1 | |
| SCHEMBL1561284 | 0.75 | MAPT (0.81) | CHEK1ACHEMAPTPIM1 | |
| SCHEMBL12666260 | 0.73 | CHEK1 (0.66) | CHEK1ACHE | |
| SCHEMBL12674281 | 0.72 | CHEK1 (0.64) | CHEK1ACHEMAPTALK | |
| SCHEMBL1893929 | 0.72 | CHEK1 (1.00) | CHEK1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216980-B2 | Methods of use of diazacarbazoles for treating cancer | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| EP-2300475-B1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH INC (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2706059-A1 | Diazacarbazoles and methods of use | Genentech, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20130261104-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-8501765-B2 | Diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2300475-A1 | DIAZACARBAZOLES AND METHODS OF USE | Genentech, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009151598-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | CHEK1 1/4885ACHE 4058/4885MAPT 4241/4885 |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | IDH3B, IDH3A, EGLN3 | CHEK1 207/4885ACHE 1733/4885MAPT 4858/4885 |
| US-20130261104-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | IDH3B, IDH3A, EGLN3 | CHEK1 207/4885ACHE 1733/4885MAPT 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.